share_log

3.1% Earnings Growth Over 1 Year Has Not Materialized Into Gains for Shinva Medical InstrumentLtd (SHSE:600587) Shareholders Over That Period

3.1% Earnings Growth Over 1 Year Has Not Materialized Into Gains for Shinva Medical InstrumentLtd (SHSE:600587) Shareholders Over That Period

一年内3.1%的收益增长并未为信华医疗仪器股份有限公司(SHSE:600587)的股东带来任何收益。
Simply Wall St ·  07/04 20:13

The simplest way to benefit from a rising market is to buy an index fund. Active investors aim to buy stocks that vastly outperform the market - but in the process, they risk under-performance. Investors in Shinva Medical Instrument Co.,Ltd. (SHSE:600587) have tasted that bitter downside in the last year, as the share price dropped 42%. That's well below the market decline of 17%. Longer term shareholders haven't suffered as badly, since the stock is down a comparatively less painful 23% in three years. More recently, the share price has dropped a further 15% in a month.

受益于上涨的市场最简单的方法就是购买指数基金。积极的投资者旨在购买远远超过市场表现的股票,但不幸的是,在此过程中,他们冒着低于市场表现的风险。在过去的一年里,新华医疗(SHSE:600587)的投资者已经尝到了这种苦涩的下跌,股价下跌了42%,远远低于市场下跌了17%。更长期的股东并没有遭受那么严重的损失,因为股票在三年内下跌了23%,相对较轻微。最近,股票价格在一个月内又下跌了15%。

If the past week is anything to go by, investor sentiment for Shinva Medical InstrumentLtd isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

如果过去一周是参考的话,新华医疗股份有限公司的投资者情绪并不乐观,因此让我们看看基本面和股票价格之间是否存在不匹配。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement.

虽然一些人仍然相信有效市场假说,但已经证明市场是过度反应的动态系统,投资者并不总是理性的。一个不完美但简单的方法来考虑公司市场看法的变化是比较每股收益(EPS)的变化和股价的波动。

Even though the Shinva Medical InstrumentLtd share price is down over the year, its EPS actually improved. It's quite possible that growth expectations may have been unreasonable in the past.

尽管新华医疗股份有限公司的股票价格在过去一年中下跌,但其每股收益实际上有所改善。过去的增长预期可能过高,这是有可能的。

By glancing at these numbers, we'd posit that the the market had expectations of much higher growth, last year. But other metrics might shed some light on why the share price is down.

通过查看这些数字,我们可以假设去年市场对增长有更高的期望。但其他指标可能会解释股价下跌的原因。

Shinva Medical InstrumentLtd managed to grow revenue over the last year, which is usually a real positive. Since the fundamental metrics don't readily explain the share price drop, there might be an opportunity if the market has overreacted.

新华医疗股份有限公司在过去一年中实现了营业收入增长,这通常是非常积极的。由于基本指标并不能立即解释股价下跌,如果市场反应过度,可能就会有机会。

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

下图显示了收益和营收随时间变化的情况(如果你点击图像,可以看到更多细节):

earnings-and-revenue-growth
SHSE:600587 Earnings and Revenue Growth July 5th 2024
营收每股收益预测数据更新时间截至2024年7月5日SHSE:600587

Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

资产负债表强度至关重要。查看我们关于其财务状况如何随时间变化的免费报告可能很值得一看。

A Different Perspective

不同的观点

We regret to report that Shinva Medical InstrumentLtd shareholders are down 40% for the year (even including dividends). Unfortunately, that's worse than the broader market decline of 17%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Longer term investors wouldn't be so upset, since they would have made 3%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand Shinva Medical InstrumentLtd better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Shinva Medical InstrumentLtd , and understanding them should be part of your investment process.

遗憾的是,新华医疗股份有限公司的股东今年股价下跌了40%(甚至包括分红派息)。不幸的是,这比更广泛的市场下跌17%还要糟。话虽如此,在下跌的市场中,一些股票注定会被超卖。关键是紧盯基本发展情况。长期投资者不会那么难过,因为他们每年都会获得3%的利润,连续五年。如果基本数据继续表明长期可持续增长,那么目前的抛售可能值得考虑。长期跟踪股价表现总是很有趣的。但是为了更好地了解新华医疗,我们需要考虑许多其他因素。比如说,不可避免的投资风险。我们已经发现了1个关于新华医疗的警告标志,了解它们应该是您投资过程的一部分。

Of course Shinva Medical InstrumentLtd may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

当然,新华医疗股份有限公司可能不是最好的购买股票。因此,您可能希望查看这个免费的成长股票集合。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

请注意,本文引用的市场回报反映了目前在中国交易所上市的股票的市场加权平均回报。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对本文有反馈?关于内容有所顾虑?直接和我们联系。或电邮 editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,也可以发送电子邮件至editorial-team@simplywallst.com

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发